Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 17/20 | 0.77 |
| ▸ | JAK2 | O60674 | 7/20 | 0.74 |
| ▸ | JAK1 | P23458 | 7/20 | 0.74 |
| ▸ | TTK | P33981 | 3/20 | 0.65 |
| ▸ | TYK2 | P29597 | 3/20 | 0.56 |
| ▸ | BTK | Q06187 | 2/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14812608 | 0.87 | JAK3 (0.78) | JAK3JAK2JAK1TTKTYK2 | |
| SCHEMBL14812483 | 0.85 | JAK3 (0.57) | JAK3JAK2JAK1TTKTYK2 | |
| SCHEMBL22648689 | 0.85 | JAK1 (1.00) | JAK3JAK2JAK1TYK2 | |
| SCHEMBL17209892 | 0.85 | JAK3 (1.00) | JAK3JAK2JAK1TYK2BTK | |
| SCHEMBL14812490 | 0.81 | JAK2 (0.55) | JAK3JAK2JAK1TYK2EGFR | |
| SCHEMBL13737455 | 0.81 | JAK2 (0.66) | JAK3JAK2JAK1TYK2EGFR | |
| SCHEMBL17209928 | 0.81 | JAK3 (0.66) | JAK3JAK2JAK1TTKTYK2 | |
| SCHEMBL13733806 | 0.81 | JAK2 (0.63) | JAK3JAK2JAK1TYK2EGFR | |
| SCHEMBL14811107 | 0.80 | JAK3 (0.66) | JAK3JAK2JAK1TTKTYK2 | |
| SCHEMBL13734235 | 0.79 | JAK2 (0.69) | JAK3JAK2JAK1TYK2AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140323504-A1 | Pyrazolo[4,3-c]Pyridine Derivatives As Kinase Inhibitors | CELLZOME LIMITED (GB) | 2014-10-30 | — | — | US | claimed |
| EP-2760863-A1 | PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | Cellzome Limited (GB) | 2014-08-06 | — | — | EP | claimed |
| WO-2013041605-A1 | PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2013-03-28 | — | — | WO | claimed |
| US-20170360796-A1 | BTK INHIBITOR COMBINATIONS AND DOSING REGIMEN | PHARMACYCLICS LLC | 2017-12-21 | — | — | US | disclosed |
| US-20160022683-A1 | COMBINATIONS OF BRUTON'S TYROSINE KINASE INHIBITORS AND CYP3A4 INHIBITORS | PHARMACYCLICS, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20160022683-A1 | COMBINATIONS OF BRUTON'S TYROSINE KINASE INHIBITORS AND CYP3A4 INHIBITORS | PHARMACYCLICS, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20140323504-A1 | Pyrazolo[4,3-c]Pyridine Derivatives As Kinase Inhibitors | CELLZOME LIMITED (GB) | 2014-10-30 | — | — | US | disclosed |
| US-20140323504-A1 | Pyrazolo[4,3-c]Pyridine Derivatives As Kinase Inhibitors | CELLZOME LIMITED (GB) | 2014-10-30 | — | — | US | disclosed |
| US-20140323504-A1 | Pyrazolo[4,3-c]Pyridine Derivatives As Kinase Inhibitors | CELLZOME LIMITED (GB) | 2014-10-30 | — | — | US | disclosed |
| EP-2760863-A1 | PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | Cellzome Limited (GB) | 2014-08-06 | — | — | EP | disclosed |
| WO-2013041605-A1 | PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013041605-A1 | PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2013-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360796-A1 | BTK INHIBITOR COMBINATIONS AND DOSING REGIMEN | BTK, SYK, ABL1 | JAK3 69/4885JAK2 19/4885JAK1 29/4885 |
| US-20160022683-A1 | COMBINATIONS OF BRUTON'S TYROSINE KINASE INHIBITORS AND CYP3A4 INHIBITORS | BTK, CYP2E1, CYP3A43 | JAK3 88/4885JAK2 75/4885JAK1 41/4885 |
| US-20140323504-A1 | Pyrazolo[4,3-c]Pyridine Derivatives As Kinase Inhibitors | MAP3K5, JAK1, MAP3K1 | JAK3 4/4885JAK2 34/4885JAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.